Pharma cos now demanding return on digital investments but some still risk being left behind
Cajoled by the pandemic and ongoing challenges with clinical trials, including studies’ low rates of technical success, protracted timelines, recruitment and retention failures, as well as ever-increasing pressures to find new revenue streams as patent cliffs draw near, drugmakers now want to see digital investments bearing fruit.
